Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 …,

(NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat …, (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat …, Read More

Scroll to Top